R. Moots

Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.

R. Moots, K. Chakravarty, B. Griffiths, 2007, Arthritis and rheumatism.

Positioning of a peptide in the cleft of HLA-A2 by complementing amino acid changes.

A. McMichael, J. Strominger, J. Rothbard, 1991, Proceedings of the National Academy of Sciences of the United States of America.

University of Birmingham Cardiovascular risk factors in women with primary Sjögren's syndrome

B. Griffiths, T. Toms, S. Bowman, 2015 .

Liver disease in twins with Felty's syndrome.

P. Emery, M. Salmon, E. Elías, 1994, Annals of the rheumatic diseases.

Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide.

J. Bell, A. McMichael, S. Rowland-Jones, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

P. Emery, J. Gottenberg, P. Sarzi-Puttini, 2014, Annals of the rheumatic diseases.

A critical role for conserved residues in the cleft of HLA-A2 in presentation of a nonapeptide to T cells.

A. McMichael, J. Strominger, M. Saper, 1992, Science.

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial

R. Moots, P. Emery, P. Durez, 2009, Annals of the rheumatic diseases.

CDP-870 (certolizumab) in rheumatoid arthritis

R. Moots, V. Kaushik, R. Moots, 2005, Expert opinion on biological therapy.